HomeCompanyTechnologyPipelinePatientsInvestors & MediaCareersContact
Back to Investors & Media

October 27, 2021


October 27, 2021

Lion TCR’s Sharing of US FDA IND Achievement at Various Conferences

Chief Operating Office and Chief Medical Officer, Dr Tina Tingting WANG represented Lion TCR at various conferences in China to share about Lion TCR’s U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) achievement for a Phase 1b/2 study for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surface antigen (HBsAg) specific TCR.

11th Oct:  Shanghai Biomedical Industry Innovation Summit  [上海(闵行)生物医药产业创新峰会]

13th Oct:  Zhangjiang Life Science International Innovation Summit (张江生命科学国际创新峰会)

27th Oct: Asia-Pacific Biomedical Cooperation Summit (亚太生物医药合作峰会)